Anthony Delalande, a research professor at a start-up in Orleans and at the CNRS's Molecular Biophysics Center, presents his work at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Dimitri Szymczak, project manager at ART-ARNm Inserm, looks on at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

A researcher looks at a vial of messenger RNA (or mRNA) being diluted, at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon poses in front of a machine producing RNA at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon poses in front of a machine producing RNA at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

A laboratory worker prepares messenger RNA (mRNA) at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon speaks at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon speaks at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)